MabCure, Inc. Study Results on a New Ovarian Cancer Diagnostic Blood Test Being Presented at the Annual Meeting of the Society of Gynecological Oncologists
ORLANDO, Fla.--(BUSINESS WIRE)--Biotechnology company MabCure, Inc. (OTCBB: MBCI) is presenting the results of its recently completed study on the diagnosis of ovarian cancer utilizing its proprietary monoclonal antibodies at the annual meeting of the Society of Gynecological Oncologists (SGO).